Ptc Therapeutics Stock Analysis

PTC Stock Analysis Notes

About 97.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.81. PTC Therapeutics recorded earning per share (EPS) of 8.6. The entity had not issued any dividends in recent years. PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. Ptc Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1167 people. To find out more about PTC Therapeutics contact Stuart Peltz at 908 222 7000 or learn more at https://www.ptcbio.com.

PTC Therapeutics Investment Alerts

PTC Largest EPS Surprises

View All Earnings Estimates

PTC Therapeutics Environmental, Social, and Governance (ESG) Scores

PTC Therapeutics Thematic Classifications

PTC Stock Institutional Investors

Note, although PTC Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

PTC Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.58 B.

PTC Profitablity

The company has Profit Margin (PM) of 0.42 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.02 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.02.

Management Efficiency

PTC Therapeutics has return on total asset (ROA) of 0.257 % which means that it generated a profit of $0.257 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (77.4012) %, meaning that it created substantial loss on money invested by shareholders. PTC Therapeutics' management efficiency ratios could be used to measure how well PTC Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 0.40 in 2026, whereas Return On Tangible Assets are likely to drop (0.23) in 2026. At this time, PTC Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 2.7 B in 2026, whereas Liabilities And Stockholders Equity is likely to drop slightly above 1.1 B in 2026.

Technical Drivers

As of the 14th of February 2026, PTC Therapeutics owns the coefficient of variation of (4,949), and Market Risk Adjusted Performance of (0.04). In relation to fundamental indicators, the technical analysis model allows you to check practical technical drivers of PTC Therapeutics, as well as the relationship between them.

PTC Therapeutics Price Movement Analysis

PTC Therapeutics Insider Trading Activities

PTC Therapeutics Outstanding Bonds

PTC Therapeutics Predictive Daily Indicators

PTC Therapeutics Corporate Filings

PTC Therapeutics Forecast Models

PTC Therapeutics' time-series forecasting models are one of many PTC Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary PTC Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

PTC Therapeutics Bond Ratings

PTC Therapeutics financial ratings play a critical role in determining how much PTC Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for PTC Therapeutics' borrowing costs.

PTC Therapeutics Debt to Cash Allocation

PTC Therapeutics currently holds 2.47 B in liabilities. PTC Therapeutics has a current ratio of 1.21, suggesting that it may have difficulties to pay its financial obligations when due. Note, when we think about PTC Therapeutics' use of debt, we should always consider it together with its cash and equity.

PTC Therapeutics Total Assets Over Time

PTC Therapeutics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which PTC Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

PTC Therapeutics Debt Ratio

137.0

It appears most of the PTC Therapeutics' assets are financed through debt. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the PTC Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of PTC Therapeutics, which in turn will lower the firm's financial flexibility.

PTC Therapeutics Corporate Bonds Issued

PTC Long Term Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how PTC Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling PTC shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as PTC Therapeutics. By using and applying PTC Stock analysis, traders can create a robust methodology for identifying PTC entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. PTC analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. PTC analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

PTC Therapeutics stock analysis indicators help investors evaluate how PTC Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading PTC Therapeutics shares will generate the highest return on investment. By understating and applying PTC Therapeutics stock analysis, traders can identify PTC Therapeutics position entry and exit signals to maximize returns.

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.